Objective To compare the efficacy and safety between and within glucagon-like peptide-1
receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) in …

Purpose To evaluate the efficacy and safety of combination therapy with sodium–glucose
cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in …

Purpose The aim of this study was to evaluate the effectiveness and safety of combination
therapy with a sodium-glucose cotransporter-2 (SGLT2) inhibitor and a glucagon-like …

Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1
receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults …

Obesity contributes to the pathogenesis of type 2 diabetes (T2DM) and cardiovascular
disease. A modest weight loss of 5–10% can have significant impact on glucose control …

Abstract GLP-1 receptor agonists (GLP-1RA) and SGLT2 inhibitors (SGLT2i) have been
associated with improved glycemic control, body weight loss and favorable changes in …

Objective This study evaluated whether adding sodium‐glucose cotransporter‐2 inhibitors
(SGLT2i) and/or glucagon‐like peptide‐1 receptor agonists (GLP1‐RA) to insulin reduced …

Context Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose
cotransporter-2 inhibitors (SGLT2is) are used off-label in the management of type 1 diabetes …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the
treatment of obesity. Objective To assess the weight-loss effects of GLP-1RAs in the …

Objective To determine effects of glucagon-like peptide-1 (GLP-1) receptor agonists on≥
5% or≥ 10% weight loss in overweight or obese patients with or without type 2 diabetes …